Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
AKAP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
AKAP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of AKAP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ABL2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ABL2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ABL2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ADCK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ADCK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ADCK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ABCG2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ABCG2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ABCG2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ABCB9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ABCB9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ABCB9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ABCB8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ABCB8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ABCB8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SORCS3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SORCS3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of SORCS3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
PLA2R1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
PLA2R1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of PLA2R1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IRS2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IRS2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IRS2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ABCB7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ABCB7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ABCB7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IMPG2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IMPG2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IMPG2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGDCC4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGDCC4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGDCC4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →